Solid Biosciences Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Solid Biosciences Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Solid Biosciences Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$35.2M, a 52.2% decline year-over-year.
  • Solid Biosciences Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$112M, a 3.82% increase year-over-year.
  • Solid Biosciences Inc. annual Operating Income (Loss) for 2023 was -$104M, a 2.07% increase from 2022.
  • Solid Biosciences Inc. annual Operating Income (Loss) for 2022 was -$106M, a 47.3% decline from 2021.
  • Solid Biosciences Inc. annual Operating Income (Loss) for 2021 was -$72.3M, a 18.3% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$112M -$35.2M -$12.1M -52.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$100M -$27.8M -$945K -3.52% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$99.1M -$26.9M +$5.17M +16.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$104M -$22.3M +$12.3M +35.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 -$117M -$23.1M -$1.98M -9.38% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$115M -$26.8M -$1.46M -5.76% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$113M -$32M -$6.66M -26.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$106M -$34.6M -$15.9M -85.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$90.5M -$21.1M -$3.1M -17.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$87.4M -$25.4M -$6.7M -35.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$80.7M -$25.4M -$8.49M -50.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$72.3M -$18.7M +$2.7M +12.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-13
Q3 2021 -$74.9M -$18M +$3.2M +15.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$78.1M -$18.7M +$289K +1.52% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$78.4M -$16.9M +$9.97M +37.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-27
Q4 2020 -$88.4M -$21.3M +$11M +34% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-23
Q3 2020 -$99.4M -$21.2M +$8.49M +28.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$108M -$19M +$8M +29.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$116M -$26.9M +$3.44M +11.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$119M -$32.3M -$9.94M -44.4% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 -$109M -$29.7M -$10.6M -55.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$98.8M -$27M -$8.79M -48.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$90M -$30.3M -$14.3M -89.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$75.7M -$22.4M -$7.23M -47.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$68.5M -$19.2M -$5.45M -39.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$63M -$18.2M -$6.29M -52.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$56.7M -$16M -$1.86M -13.2% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$54.9M -$15.2M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-13
Q3 2017 -$13.7M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-13
Q2 2017 -$11.9M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-13
Q1 2017 -$14.1M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.